Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a 15% topical minoxidil solution improved hair regrowth in 60% of women with female pattern hair loss who did not respond to the standard 5% solution, without adverse effects.

Low-dose naltrexone helps improve symptoms and stabilize frontal fibrosing alopecia and lichen planopilaris.

This study found that 1 mg/day low-dose oral minoxidil significantly increased hair count compared to 0.25 mg/day over 24 weeks in women with female pattern hair loss, though no differences were observed in hair-shedding and quality-of-life scores between the two doses.

This study reports that γ-ray exposure in rats led to dermal endothelial proliferation, new vessel formation around hair follicles, and increased inflammatory markers, suggesting possible early stimulatory effects on hair growth.

This report shares the authors' experience using spironolactone for treating acne in a PCOS clinic, but provides no new clinical results.

Low-dose finasteride may cause muscle weakness and eye issues, but stopping the drug can lead to recovery.

Low-dose oral minoxidil can cause dizziness in women without lowering blood pressure, so careful monitoring is needed.

Low-dose oral minoxidil combined with topical minoxidil improves hair density in breast cancer patients but may cause excess hair growth.

This study aims to evaluate the efficacy and safety of combining low-dose oral minoxidil with spironolactone for treating female androgenetic alopecia, amid concerns about potential blood pressure effects, though the results are not reported here.

In this study, low-dose naltrexone significantly reduced erythema in patients with frontal fibrosing alopecia and lichen planopilaris after one year, but no significant improvements were seen in other symptoms.

In this study, researchers aimed to evaluate the safety and tolerability of low-dose oral minoxidil in adolescents, as existing data on its use in this population are limited and there are no specific pediatric guidelines for prescribing it. Results are not reported.

This study found that for people with androgenetic alopecia, increasing the dosage of low-dose oral minoxidil is associated with improvements in hair diameter and density, but also raises the risk of hypertrichosis and cardiovascular adverse events.

This commentary highlights the consistency of recent findings on low-dose oral minoxidil's tolerability for androgenetic alopecia, noting infrequent side effects except for hypertrichosis.

In this study, Alhanshali and co-authors reported that low-dose oral minoxidil, used for treating androgenetic alopecia, may worsen hangover symptoms in some male patients, potentially due to interactions with alcohol that affect blood pressure and metabolic processes.

This study highlights the complex clinical issues associated with using low dose oral minoxidil for alopecia, emphasizing the need for careful cardiology-dermatology collaboration due to rare but serious cardiovascular risks, especially in patients with existing cardiorenal or cardiovascular concerns.

This case report describes a patient with lichen planopilaris who experienced remarkable hair regrowth at a previously scarred area after treatment with low-dose naltrexone and platelet-rich plasma, following minimal response to other therapies.

This study reviewed literature on low-dose oral minoxidil as a treatment for hair loss, finding good compliance and tolerability, with mild adverse effects like hypertrichosis, which increase with higher doses.

This study observed that low-dose intrauterine exposure to finasteride alters postnatal prostate development in male and female Mongolian gerbils, showing sex-specific differences in receptor expression and tissue changes.

This study found that high concentrations of supplemental cobalt inhibited hair follicle development in rabbits, potentially involving the mTOR-BMP signaling pathway.

In this study, low-dose oral minoxidil for androgenetic alopecia was generally safe, showing small average changes in blood pressure and heart rate with infrequent cardiovascular issues, though monitoring is essential, especially in patients with conditions like hypertension or arrhythmias.

Low-dose oral minoxidil is effective and satisfying for treating hair loss in young people.

This study reviewed evidence on cutaneous reactions and associated radiation doses from cranial or spinal neurointerventional procedures, finding that alopecia/epilation was most common and onset doses often aligned with known thresholds, highlighting the need for standardized dose reporting and follow-up.

In this randomized controlled trial, researchers found that a 2.5 mg daily dose of oral minoxidil was more effective than a 1 mg dose in improving hair growth parameters in patients with androgenetic alopecia over three months, with both doses being well tolerated.

This review suggests that low-dose oral minoxidil may enhance hair density in certain nonandrogenetic alopecias, but highlights the need for controlled trials due to mixed and limited evidence.

This study found that escalating baricitinib to 6 mg daily improved hair loss in 75% of patients with severe refractory alopecia areata who responded poorly to standard treatments, while also noting manageable short-term safety concerns under close monitoring.

This study used a probabilistic framework to show that platelet-rich plasma preparation results in significant variability in platelet dose due to factors like injected volume and concentration factor.

This prospective study observed that low-dose oral minoxidil improved anterior hairline and eyebrow coverage in adult women with frontal fibrosing alopecia and was generally well-tolerated.

This study developed consensus guidelines for the use of low-dose oral and topical minoxidil in male and female pattern hair loss, recommending specific doses, monitoring procedures, and timing of application around hair transplant surgeries.